Full Press Release Details
Announces Closing of Over-Allotment Option
Connection with its Initial Public Offering
MA, July 1, 2021 /PRNewswire/ - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online
marketplace for human biospecimens, today announced the closing of the issuance of an additional 337,500 shares of its common stock pursuant
to the full exercise of the underwriters' over-allotment option in connection with the Company's initial public offering
(the "IPO"). The additional shares were sold at the initial offering price of $8.00 per share, resulting in additional gross
proceeds of $2,700,000 and bringing the total gross proceeds of the IPO to $20,700,000.
shares of common stock began trading on the Nasdaq Capital Market under the ticker symbol "ISPC" on June 17, 2021.
a division of Fordham Financial Management, Inc., acted as the sole book-running manager for the IPO of the Company.
registration statement relating to the IPO was declared effective by the Securities and Exchange Commission ("SEC") on June
16, 2021. A final prospectus related to the IPO was filed and is available on the SEC's website at www.sec.gov. The
IPO was made only by means of a prospectus. Electronic copies of the final prospectus may be obtained from ThinkEquity, a division of
Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673
and by email at prospectus@think-equity.com.
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare
providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists
to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.
press release contains statements that constitute "forward-looking statements," including with respect to the IPO and the anticipated
use of the net proceeds. No assurance can be given that the net proceeds of the IPO will be used as indicated. Forward-looking statements
are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors
section of the Company's registration statement and final prospectus for the Company's offering filed with the SEC. Copies of these
documents are available on the SEC's website at www.sec.gov. The Company undertakes no obligation to update these statements
for revisions or changes after the date of this release, except as required by law.
further information, please contact:
Strategic Communications
Soss / Scott Eckstein
Lejnieks, Sr. Director of Marketing